Krystal Biotech (NASDAQ:KRYS) Given New $215.00 Price Target at Citigroup

Krystal Biotech (NASDAQ:KRYS) had its price target increased by equities researchers at Citigroup from $206.00 to $215.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price objective points to a potential upside of 18.21% from the stock’s current price.

A number of other research analysts have also recently commented on KRYS. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. Finally, Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Trading Up 3.2 %

Shares of Krystal Biotech stock traded up $5.71 during trading on Thursday, hitting $181.88. The stock had a trading volume of 293,635 shares, compared to its average volume of 251,577. The firm has a market cap of $5.23 billion, a price-to-earnings ratio of 102.62 and a beta of 0.84. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The business’s 50-day moving average is $157.18 and its 200 day moving average is $175.18.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 earnings per share. As a group, equities analysts expect that Krystal Biotech will post 3.22 EPS for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Krystal Biotech during the fourth quarter valued at about $95,000. Palisades Investment Partners LLC boosted its holdings in shares of Krystal Biotech by 9.3% during the fourth quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock worth $6,341,000 after purchasing an additional 3,436 shares during the period. Woodline Partners LP boosted its holdings in shares of Krystal Biotech by 23.0% during the fourth quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock worth $34,638,000 after purchasing an additional 41,287 shares during the period. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Krystal Biotech by 28.6% during the fourth quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock worth $1,386,000 after purchasing an additional 1,967 shares during the period. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).